The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Suzetrigine is a sodium channel blocker, the same type of drug as lidocaine. Lidocaine, a local anesthetic, works by blocking ...